Our deep-rooted commitment to and with patients has once again been rewarded: we have once again made significant improvement in PatientView’s ranking of pharmaceutical company reputation among patient organizations. For the second year running, we have secured our position in the top 3 in oncology and placed first in several categories in the United States.
On the global podium for oncology
At a global level, we are proud to maintain our position in the top 3 of the PatientView survey of the reputations of pharmaceutical companies working with oncology patient organizations worldwide. For the first time, we came first in three categories: “Transparency on Data,” “Beyond the pill,” and “R&D.”
All therapeutic areas combined we ranked 11th (up 3 places) in the survey of patient organizations working with us. This is yet another demonstration of our commitment to working ever more closely with patients and the patient organizations that represent them, particularly in oncology!
“These results illustrate our ability to form strong and lasting relationships in our partnerships with the community of patients at each step of their health care journey. These collaborations with patients and patient organizations are crucial throughout the care process, but also and above all at the various stages of healthcare innovation. I would like to thank the patient organizations for the trust they place in us.”
Nicolas Garnier, Chief Patient Officier, Servier
3rd/26
among patient organizations working with pharmaceutical groups in oncology
11th/41
among patient organizations working with pharmaceutical groups (all therapeutic areas combined)
2,500
The 2023 PatientView survey collected feedback from more than 2,500 patient organizations across the world
In the United States: Patient engagement at its highest
We ranked first in twelve of the fourteen categories in the rankings drawn up by patient organizations familiar with the Servier Group in the United States. This is a first for a French pharmaceutical company!
These impressive results for our subsidiary are the result of close collaboration with patients and patient organizations. They reflect the true expression of our vocation, which is for therapeutic progress to serve patient needs.
Patients at the heart of everything we do
Throughout the year, and all over the world, we strengthened and established new collaborations with patients and the organizations that represent them. One of the best examples of this is the creation of expert patient committees to work with us on major projects. Comprising 18 patients representing ten different pathologies1, the Servier Saclay Research & Development Patient Board has been working with our R&D teams so that patients’ views are even more effectively integrated into the new medicine research and development process.
Servier is currently collaborating on more than 250 projects with patient groups around the world.
[1] Patient volunteers who applied to participate in EUPATI (European Patients’ Academy on Therapeutic Innovation), an innovative pan-European initiative involving 33 organizations, led by the European Patients’ Forum with partners from patient organizations, universities and nonprofits, as well as a number of European pharmaceutical companies.
